PO.MCB05.01 · 分子与细胞生物学

Dynamic and defective repair of extrachromosomal DNA drives genome instability in cancer

海报缩略图:Dynamic and defective repair of extrachromosomal DNA drives genome instability in cancer
编号 4689 展板 9 时间 4/21 09:00–12:00 区域 Section 21 主讲 Shu Zhang, BS;PhD
分会场 Insights into Genomic Instability
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Shu Zhang1, Yanbo Wang2, Thomas B. K. Watkins1, Xiaowei Yan3, Aditi Gnanasekar3, Jun Tang3, Ivy T. Wong3, Howard Y. Chang4, Paul S. Mischel2

1Pathology, Stanford University, Stanford, CA,2Stanford University School of Medicine, Stanford, CA,3Stanford University, Stanford, CA,4Amgen, Stanford, CA

摘要 Abstract

Extrachromosomal DNA (ecDNA) is megabase-sized circular DNA amplified exclusively in tumor cells, driving poor outcomes and therapeutic resistance. EcDNA represents a distinct form of genome instability associated with heightened replication stress and DNA damage. However, how ecDNA manages these elevated damage levels remains unclear. Here, we used long-read sequencing and live-cell imaging to investigate DNA damage repair dynamics and genomic patterns in isogenic cell lines harboring either ecDNA or homogeneously staining region (HSR). We found that damaged ecDNAs are preferentially sequestered into micronuclei following induction of double-strand breaks. This process triggers additional DNA damage beyond the initial lesions and impairs homologous recombination (HR) during knock-in by CRISPR-Cas9. Structural variant analyses further revealed that although ecDNA damage initiates HR repair, the process is frequently incomplete or aberrant. Analysis of whole-genome sequencing data from 14,778 tumors across 39 cancer types in the Genomics England cohort confirmed that ecDNA-positive cancers exhibit enriched HR deficiency (HRD) mutational signatures, even after excluding cases with canonical HRD driver mutations. Together, these findings delineate the dynamic and error-prone repair of ecDNA, linking it to HRD-associated genomic alterations. Our study exposes vulnerabilities of ecDNA-positive cancers that may be therapeutically exploited through synthetic lethality related to HRD.
利益披露 Disclosure
S. Zhang, None.. T. B. K. Watkins, None.

在会议检索中打开